| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2013117649 |
| Title |
Imidazo [4, 5 -C] Pyridine Derivatives Useful for The Treatment of Degenerative and Inflammatory Diseases. |
| Abstract |
Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. |
| Applicant(s) |
Galapagos Nv |
| Patent ID |
WO2013117646 |
| Title |
Novel Compound Useful for The Treatment of Degenerative and Inflammatory Diseases. |
| Abstract |
A novel imidazolopyridine according to Formula I, able to inhibit JAK as disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. |
| Applicant(s) |
Galapagos Nv |
| Patent ID |
WO2013117645 |
| Title |
Imidazo [4, 5 -C] Pyridine Derivatives Useful for The Treatment of Degenerative and Inflammatory Diseases. |
| Abstract |
Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. |
| Applicant(s) |
Galapagos Nv |
| Representative Drug(s) |
D07PTU |
Drug Info
|
IC50 = 1 to 500 nM |
[1] |
| Patent ID |
WO2013033093 |
| Title |
Heterocyclic Compounds As Janus Kinase Inhibitors. |
| Abstract |
The invention provides compounds of formula I: (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer, including a hematologic malignancy, using compounds of formula I. |
| Applicant(s) |
Biocryst Pharmaceuticals, Inc |
| Representative Drug(s) |
D05PDI |
Drug Info
|
IC50 < 1000 nM |
[1] |
| Patent ID |
WO2014074471 |
| Title |
Methods for Treating Inflammatory Diseases and Pharmaceutical Combinations Useful Therefor. |
| Abstract |
The present invention provides a method of treating psoriasis comprising the administration of a compound of Formula I or a compound of Formula I and a co-therapy, and administrations of pharmaceutical compositions comprising a compound of Formula (I). |
| Applicant(s) |
Vertex Pharmaceuticals Incorporated |
| Representative Drug(s) |
D0GH8D |
Drug Info
|
N.A. |
[2] |
| Patent ID |
WO2014051654 |
| Title |
Bicyclic Oxa-Lactam Kinase Inhibitors. |
| Abstract |
Provided are bicyclic oxa-lactam compounds for inhibition of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity. |
| Applicant(s) |
Portola Pharmaceuticals, Inc |
| Patent ID |
WO2014051653 |
| Title |
Bicyclic Dihydropyridone Kinase Inhibitors. |
| Abstract |
Provided are bicyclic dihydropyridone compounds for inhibiting of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity. |
| Applicant(s) |
Portola Pharmaceuticals, Inc |
| Patent ID |
WO2013189771 |
| Title |
Aminotriazolopyridine for Use In The Treatment of Inflammation, and Pharmaceutical Compositions Thereof. |
| Abstract |
The present invention relates to the novel medical use of the compound according to Formula I, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound. |
| Applicant(s) |
Galapagos Nv |
| Representative Drug(s) |
D09ALF |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013188783 |
| Title |
Deuterated Derivatives of Ruxolitinib. |
| Abstract |
The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein. |
| Applicant(s) |
Concert Pharmaceuticals, Inc |
| Representative Drug(s) |
D04XNL |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2008106635 |
| Title |
Pyrimidine-2,4-Diamine Derivatives and Their Use As Jak2 Kinase Inhibitors. |
| Abstract |
Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions. |
| Applicant(s) |
Supergen, Inc |
| Representative Drug(s) |
D0D8MK |
Drug Info
|
N.A. |
[2] |
| Patent ID |
WO2015027005 |
| Title |
Isotopically Enriched Azaindoles. |
| Abstract |
The present invention relates to a deuterated pyrrolo[2,3-b]pyridinyl compound that is useful for inhibiting Janus kinases. The invention also relates to processes and intermediates useful for preparing such a compound. |
| Applicant(s) |
Vertex Pharmaceuticals Incorporated |
| Patent ID |
WO2014201332 |
| Title |
Pharmaceutical Combinations Useful for Treating Rheumatoid Arthritis. |
| Abstract |
The present invention provides a method of treating or lessening the severity of a disease or disorder mediated by an abnormal immune response (e.g., rheumatoid arthritis) comprising the administration of a compound of Formula I and a corticosteroid. |
| Applicant(s) |
Vertex Pharmaceuticals Incorporated |
| Patent ID |
WO2014110259 |
| Title |
Solid forms of A Jak Inhibitor. |
| Abstract |
The present invention relates to solid state forms of JAK inhibitor (R)-2-(2-(lH-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide (Compound 1) including solvates, salts, co-crystals, and an amorphous form thereof. The present invention also provides pharmaceutical compositions comprising these solid forms of Compound 1 and methods of treating a JAK mediated disease therewith. |
| Applicant(s) |
Vertex Pharmaceuticals Incorporated |
| Patent ID |
WO2014028756 |
| Title |
Deuterated Baricitinib. |
| Abstract |
The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification. |
| Applicant(s) |
Concert Pharmaceuticals, Inc |
| Patent ID |
WO2012022681 |
| Title |
Heterocyclyl Pyrazolopyrimidine Analogues As Selective Jak Inhibitors. |
| Abstract |
The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments. |
| Applicant(s) |
Cellzome Limited |
| Patent ID |
WO2011068881 |
| Title |
Novel Tricyclic Compounds. |
| Abstract |
The invention provides compounds of Formula (I) and Formula (II), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. |
| Applicant(s) |
Abbott Laboratories |
| Patent ID |
WO2011048082 |
| Title |
Heterocyclyl Pyrazolopyrimidine Analogues As Jak Inhibitors. |
| Abstract |
The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments. |
| Applicant(s) |
Cellzome Limited |
| Patent ID |
WO2011003065 |
| Title |
Pyrazolopyrimidine Jak Inhibitor Compounds and Methods. |
| Abstract |
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO2010051549 |
| Title |
Pyrazolopyrimidine Jak Inhibitor Compounds and Methods. |
| Abstract |
The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient. Ia. |
| Applicant(s) |
Genentech, Inc |
| Patent ID |
WO201415951 |
| Title |
Deuterated Pacritinib. |
| Applicant(s) |
Concert Pharmaceuticals Inc |
